Henry Schein (NASDAQ:HSIC) Director Sells $228,543.84 in Stock

Henry Schein, Inc. (NASDAQ:HSIC) Director Philip Laskawy sold 2,844 shares of the firm’s stock in a transaction that occurred on Thursday, March 5th. The shares were sold at an average price of $80.36, for a total transaction of $228,543.84. Following the completion of the transaction, the director directly owned 21,961 shares in the company, valued at approximately $1,764,785.96. The trade was a 11.47% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through the SEC website.

Henry Schein Price Performance

HSIC opened at $77.60 on Monday. The company has a fifty day moving average price of $78.20 and a two-hundred day moving average price of $72.63. The firm has a market capitalization of $8.90 billion, a PE ratio of 23.73, a P/E/G ratio of 2.30 and a beta of 0.87. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.76 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last posted its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating analysts’ consensus estimates of $1.30 by $0.04. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The company had revenue of $3.44 billion for the quarter, compared to the consensus estimate of $3.34 billion. During the same quarter in the prior year, the business posted $1.19 EPS. The firm’s quarterly revenue was up 7.7% on a year-over-year basis. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, analysts anticipate that Henry Schein, Inc. will post 4.74 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. AQR Capital Management LLC lifted its holdings in shares of Henry Schein by 47.3% during the 1st quarter. AQR Capital Management LLC now owns 30,402 shares of the company’s stock valued at $2,071,000 after purchasing an additional 9,756 shares in the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its position in shares of Henry Schein by 1.4% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 16,859 shares of the company’s stock valued at $1,155,000 after purchasing an additional 229 shares during the period. Acadian Asset Management LLC bought a new stake in Henry Schein during the 1st quarter worth approximately $676,000. Envestnet Asset Management Inc. raised its holdings in Henry Schein by 103.1% during the 2nd quarter. Envestnet Asset Management Inc. now owns 91,299 shares of the company’s stock worth $6,669,000 after buying an additional 46,357 shares during the period. Finally, Atria Investments Inc acquired a new stake in Henry Schein during the 2nd quarter worth approximately $458,000. 96.62% of the stock is owned by institutional investors and hedge funds.

Analyst Ratings Changes

HSIC has been the topic of a number of recent analyst reports. Leerink Partners raised their target price on Henry Schein from $75.00 to $87.00 and gave the stock a “market perform” rating in a report on Tuesday, February 24th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Henry Schein in a research note on Monday, December 29th. Barclays initiated coverage on shares of Henry Schein in a research report on Monday, December 8th. They issued an “overweight” rating and a $86.00 price target on the stock. Wells Fargo & Company boosted their price objective on shares of Henry Schein from $76.00 to $87.00 and gave the company an “equal weight” rating in a report on Wednesday, February 25th. Finally, Robert W. Baird set a $100.00 target price on shares of Henry Schein and gave the company an “outperform” rating in a research note on Monday, February 23rd. Six research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat, the company presently has a consensus rating of “Hold” and a consensus target price of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.